 Catherine Obrien
Concepts (151)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 12 | 2021 | 151 | 3.030 |
Why?
| | Students, Pharmacy | 5 | 2019 | 123 | 1.490 |
Why?
| | Patient-Centered Care | 2 | 2019 | 129 | 1.140 |
Why?
| | Education, Pharmacy | 5 | 2019 | 144 | 1.000 |
Why?
| | Professional-Patient Relations | 3 | 2019 | 46 | 0.910 |
Why?
| | Schools, Pharmacy | 3 | 2019 | 52 | 0.830 |
Why?
| | Alprostadil | 2 | 2011 | 10 | 0.730 |
Why?
| | Educational Measurement | 5 | 2019 | 204 | 0.720 |
Why?
| | Constipation | 2 | 2011 | 33 | 0.720 |
Why?
| | Pharmacists | 2 | 2019 | 143 | 0.620 |
Why?
| | Curriculum | 7 | 2019 | 397 | 0.590 |
Why?
| | Radius | 1 | 2018 | 27 | 0.590 |
Why?
| | Neutrophils | 2 | 2015 | 148 | 0.520 |
Why?
| | Respiratory System | 1 | 2015 | 27 | 0.510 |
Why?
| | Respiratory Tract Infections | 1 | 2015 | 76 | 0.480 |
Why?
| | Tracheostomy | 1 | 2015 | 71 | 0.480 |
Why?
| | Dietary Supplements | 2 | 2012 | 445 | 0.470 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2016 | 489 | 0.450 |
Why?
| | Gastric Acid | 1 | 2013 | 9 | 0.440 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2013 | 24 | 0.440 |
Why?
| | Dietetics | 1 | 2012 | 11 | 0.420 |
Why?
| | Nutrition Therapy | 1 | 2012 | 20 | 0.420 |
Why?
| | Lymphocytes | 1 | 2013 | 154 | 0.410 |
Why?
| | Lung | 2 | 2013 | 507 | 0.410 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 1160 | 0.400 |
Why?
| | Enteral Nutrition | 1 | 2012 | 150 | 0.390 |
Why?
| | Motivational Interviewing | 2 | 2019 | 32 | 0.320 |
Why?
| | Cesium | 1 | 2008 | 8 | 0.310 |
Why?
| | Pharmaceutical Services | 2 | 2019 | 52 | 0.310 |
Why?
| | Chlorides | 1 | 2008 | 50 | 0.310 |
Why?
| | Humans | 23 | 2021 | 50201 | 0.300 |
Why?
| | Problem-Based Learning | 1 | 2008 | 47 | 0.300 |
Why?
| | Pseudomonas Infections | 2 | 2019 | 50 | 0.290 |
Why?
| | Pseudomonas aeruginosa | 2 | 2019 | 74 | 0.290 |
Why?
| | Education, Medical, Undergraduate | 1 | 2008 | 83 | 0.290 |
Why?
| | Pilot Projects | 4 | 2018 | 703 | 0.280 |
Why?
| | Electrocardiography | 1 | 2008 | 259 | 0.270 |
Why?
| | Students, Medical | 1 | 2008 | 159 | 0.260 |
Why?
| | Child | 7 | 2018 | 6862 | 0.250 |
Why?
| | Depression | 2 | 2021 | 571 | 0.250 |
Why?
| | Adolescent | 7 | 2015 | 6459 | 0.240 |
Why?
| | Female | 13 | 2019 | 26829 | 0.230 |
Why?
| | Male | 12 | 2019 | 25572 | 0.220 |
Why?
| | Infant | 4 | 2015 | 3584 | 0.220 |
Why?
| | Anti-Bacterial Agents | 2 | 2019 | 744 | 0.200 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 44 | 0.190 |
Why?
| | Vitamin D | 1 | 2012 | 88 | 0.190 |
Why?
| | College Admission Test | 2 | 2018 | 13 | 0.190 |
Why?
| | School Admission Criteria | 2 | 2018 | 35 | 0.180 |
Why?
| | Chloride Channels | 2 | 2011 | 26 | 0.180 |
Why?
| | Forced Expiratory Volume | 3 | 2019 | 44 | 0.180 |
Why?
| | Off-Label Use | 1 | 2019 | 26 | 0.170 |
Why?
| | Pneumonia, Bacterial | 1 | 2019 | 27 | 0.170 |
Why?
| | Airway Management | 1 | 2019 | 19 | 0.160 |
Why?
| | Mass Screening | 1 | 2012 | 348 | 0.160 |
Why?
| | Self Efficacy | 1 | 2019 | 130 | 0.150 |
Why?
| | Patient Compliance | 1 | 2019 | 230 | 0.150 |
Why?
| | Communication | 1 | 2019 | 246 | 0.140 |
Why?
| | Retrospective Studies | 4 | 2018 | 6190 | 0.140 |
Why?
| | Absorptiometry, Photon | 1 | 2018 | 155 | 0.140 |
Why?
| | Adult | 8 | 2021 | 13486 | 0.140 |
Why?
| | Case-Control Studies | 2 | 2018 | 1145 | 0.140 |
Why?
| | Health Behavior | 1 | 2019 | 250 | 0.140 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2016 | 19 | 0.130 |
Why?
| | Young Adult | 4 | 2018 | 4052 | 0.130 |
Why?
| | Drug Repositioning | 1 | 2015 | 11 | 0.130 |
Why?
| | Bone Density | 1 | 2018 | 386 | 0.130 |
Why?
| | Fenofibrate | 1 | 2015 | 16 | 0.130 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 77 | 0.120 |
Why?
| | Quinolines | 1 | 2015 | 41 | 0.120 |
Why?
| | Acetates | 1 | 2015 | 49 | 0.120 |
Why?
| | Megacolon, Toxic | 1 | 2013 | 3 | 0.110 |
Why?
| | Epithelial Cells | 1 | 2015 | 210 | 0.110 |
Why?
| | Antacids | 1 | 2013 | 11 | 0.110 |
Why?
| | Leukocyte Count | 1 | 2013 | 72 | 0.110 |
Why?
| | Colon | 1 | 2013 | 96 | 0.110 |
Why?
| | Appetite Stimulants | 1 | 2012 | 5 | 0.110 |
Why?
| | Fatal Outcome | 1 | 2013 | 195 | 0.110 |
Why?
| | Enzymes | 1 | 2012 | 30 | 0.110 |
Why?
| | Proton Pump Inhibitors | 1 | 2013 | 84 | 0.100 |
Why?
| | Staphylococcal Infections | 1 | 2015 | 269 | 0.100 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 1580 | 0.100 |
Why?
| | Gastrostomy | 1 | 2012 | 56 | 0.100 |
Why?
| | Zinc | 1 | 2012 | 53 | 0.100 |
Why?
| | Health Care Surveys | 1 | 2012 | 173 | 0.100 |
Why?
| | Dietary Fats | 1 | 2012 | 125 | 0.100 |
Why?
| | Bone Diseases | 1 | 2012 | 97 | 0.100 |
Why?
| | Biopsy | 1 | 2013 | 592 | 0.090 |
Why?
| | Body Composition | 1 | 2013 | 326 | 0.090 |
Why?
| | Asthma | 1 | 2015 | 282 | 0.090 |
Why?
| | Inflammation | 1 | 2015 | 608 | 0.090 |
Why?
| | Diet, High-Fat | 1 | 2012 | 214 | 0.090 |
Why?
| | Body Mass Index | 1 | 2013 | 658 | 0.090 |
Why?
| | Mental Disorders | 1 | 2015 | 400 | 0.090 |
Why?
| | Internet | 1 | 2012 | 261 | 0.090 |
Why?
| | Treatment Outcome | 2 | 2011 | 5203 | 0.090 |
Why?
| | Secondary Prevention | 1 | 2010 | 79 | 0.080 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2010 | 36 | 0.080 |
Why?
| | Intestinal Obstruction | 1 | 2010 | 36 | 0.080 |
Why?
| | Coronary Artery Disease | 1 | 2012 | 273 | 0.080 |
Why?
| | Biphenyl Compounds | 1 | 2008 | 31 | 0.080 |
Why?
| | Adaptation, Psychological | 2 | 2021 | 226 | 0.080 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 43 | 0.080 |
Why?
| | Infant, Newborn | 1 | 2015 | 2770 | 0.080 |
Why?
| | Tetrazoles | 1 | 2008 | 40 | 0.080 |
Why?
| | Self-Assessment | 1 | 2008 | 44 | 0.080 |
Why?
| | Benzimidazoles | 1 | 2008 | 49 | 0.080 |
Why?
| | Peer Group | 1 | 2008 | 54 | 0.070 |
Why?
| | Longitudinal Studies | 2 | 2021 | 700 | 0.070 |
Why?
| | Program Development | 1 | 2008 | 162 | 0.070 |
Why?
| | Child, Preschool | 1 | 2015 | 3896 | 0.070 |
Why?
| | Program Evaluation | 1 | 2008 | 347 | 0.070 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2008 | 196 | 0.060 |
Why?
| | Blood Pressure | 1 | 2008 | 527 | 0.060 |
Why?
| | Clinical Competence | 1 | 2008 | 397 | 0.060 |
Why?
| | Risk Factors | 1 | 2013 | 3644 | 0.060 |
Why?
| | Liver Neoplasms | 1 | 2008 | 331 | 0.060 |
Why?
| | Hypertension | 1 | 2008 | 541 | 0.050 |
Why?
| | Logistic Models | 2 | 2016 | 901 | 0.050 |
Why?
| | Ergocalciferols | 1 | 2012 | 1 | 0.050 |
Why?
| | 25-Hydroxyvitamin D 2 | 1 | 2012 | 2 | 0.050 |
Why?
| | Calcifediol | 1 | 2012 | 8 | 0.050 |
Why?
| | Malabsorption Syndromes | 1 | 2012 | 9 | 0.050 |
Why?
| | Cholecalciferol | 1 | 2012 | 22 | 0.050 |
Why?
| | Seasons | 1 | 2012 | 81 | 0.050 |
Why?
| | Evidence-Based Practice | 1 | 2012 | 97 | 0.050 |
Why?
| | Spirituality | 1 | 2021 | 30 | 0.050 |
Why?
| | Administration, Inhalation | 1 | 2019 | 111 | 0.040 |
Why?
| | Respiratory Function Tests | 1 | 2019 | 88 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2015 | 1356 | 0.040 |
Why?
| | Middle Aged | 3 | 2019 | 12356 | 0.040 |
Why?
| | Age Factors | 1 | 2012 | 1096 | 0.040 |
Why?
| | Pharmacy | 1 | 2018 | 54 | 0.040 |
Why?
| | Social Support | 1 | 2019 | 263 | 0.040 |
Why?
| | Universities | 1 | 2018 | 169 | 0.040 |
Why?
| | Anxiety | 1 | 2019 | 276 | 0.030 |
Why?
| | Disease Progression | 1 | 2019 | 821 | 0.030 |
Why?
| | Chemokine CXCL5 | 1 | 2015 | 5 | 0.030 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 54 | 0.030 |
Why?
| | Bronchi | 1 | 2015 | 44 | 0.030 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2015 | 60 | 0.030 |
Why?
| | Chemokines | 1 | 2015 | 76 | 0.030 |
Why?
| | Interleukin-8 | 1 | 2015 | 86 | 0.030 |
Why?
| | Sulfides | 1 | 2015 | 28 | 0.030 |
Why?
| | Cyclopropanes | 1 | 2015 | 24 | 0.030 |
Why?
| | Anti-Asthmatic Agents | 1 | 2015 | 29 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2015 | 388 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2015 | 1587 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2015 | 1029 | 0.020 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2008 | 35 | 0.020 |
Why?
| | United States | 1 | 2019 | 4898 | 0.020 |
Why?
|
|
Obrien's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|